ObsEva's Common Shares To Be Suspended By Nasdaq On March 23

ObsEva SA (OBSV) said Wednesday that it received a notification letter from the Nasdaq Stock Market, advising the company that its securities are scheduled for delisting from the Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. But the company intends to maintain its SIX Swiss Exchange listing where all common shares may continue to trade under the ticker symbol "OBSN".

The company said it had received a notification letter on September 12, 2022 from Nasdaq advising it that it was not in compliance with Listing Rule, because, for a period of thirty consecutive business days, the bid price of ObsEva's common shares had closed below the minimum $1.00 per share requirement for continued listing. The company was provided 180 calendar days, or until March 13, 2023, to regain compliance with the Rule. The Company has not regained compliance by this deadline.

The company intends to file with the SEC a Form 15 requesting deregistration of its securities.

The company expects the Nasdaq delisting and SEC deregistration to contribute to lower general and administrative costs in the future.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT